Skip to main content

%1

This Nonprofit Health System Cuts Off Patients With Medical Debt

Submitted by jhartgen@abi.org on

Many hospitals in the United States use aggressive tactics to collect medical debt. But a wealthy nonprofit health system in the Midwest is among those taking things a step further: withholding care from patients who have unpaid medical bills, the New York Times reported. Allina Health System, which runs more than 100 hospitals and clinics in Minnesota and Wisconsin and brings in $4 billion a year in revenue, sometimes rejects patients who are deep in debt, according to internal documents and interviews with doctors, nurses and patients. Although Allina’s hospitals will treat anyone in emergency rooms, other services can be cut off for indebted patients, including children and those with chronic illnesses like diabetes and depression. Patients aren’t allowed back until they pay off their debt entirely. Nonprofit hospitals like Allina get enormous tax breaks in exchange for providing care for the poorest people in their communities. But a New York Times investigation last year found that over the past several decades, nonprofits have fallen short of their charitable missions, with few consequences. Allina has an explicit policy for cutting off patients who owe money for services they received at the health system’s 90 clinics. A 12-page document reviewed by the Times instructs Allina’s staff on how to cancel appointments for patients with at least $4,500 of unpaid debt. The policy walks through how to lock their electronic health records so that staff cannot schedule future appointments.

Article Tags

KKR-Backed Radiotherapy Group GenesisCare Files for Bankruptcy

Submitted by jhartgen@abi.org on

The cancer-treatment specialist GenesisCare has filed for bankruptcy protection, after struggling under a debt load enlarged by a $1.5 billion takeover, the Wall Street Journal reported. Australia-based GenesisCare said today that it would split its U.S. business from operations in Australia, Spain and the U.K. as part of the U.S. chapter 11 reorganization. GenesisCare didn't say how much debt would be affected by the filing. GenesisCare is backed by the U.S. private-equity giant KKR. Starting with a single clinic in 2005, it has grown to more than 300 locations in four countries and over 5,500 employees. “The past three years have presented significant operational and financial challenges, requiring a comprehensive restructuring of the operations and balance sheet of the company,” David Young, who started as GenesisCare’s chief executive in April, said in a statement. GenesisCare has secured $200 million of debtor-in-possession financing from existing lenders, and plans to continue operating without disruption to patient care.

Makers of COVID-19 Treatments Hit by Falling Demand

Submitted by jhartgen@abi.org on

Allied Healthcare Products, a respiratory medical-devices maker, spent hundreds of thousands of dollars in 2020 expanding its product line to meet what it believed would be a surge in demand for ventilators at the onset of the pandemic. By the time it churned out more machines, demand fell short of expectations. Earlier this month, the company filed for bankruptcy and plans to sell its assets, WSJ Pro Bankruptcy reported. “Having diverted a lot of resources — time, personnel, floor and machine space — to ventilator production, Allied found it had an inventory of ventilators it couldn’t sell,” Eric Peterson, the St. Louis, Mo.-based company’s lawyer, said at a hearing earlier this month. Other healthcare suppliers, including a vial manufacturer and a COVID-19 test-kit maker, are among companies that have filed for chapter 11 bankruptcy. Many such companies are rattled by diminishing sales as pandemic worries recede, and they are now burdened with products piling up in storage. “More than anything I’ve ever seen, COVID chose winners and losers during the lockdown, and it is determining winners and losers now,” said Ken Mann, managing director for investment bank SC&H Capital. Vial manufacturer SiO2 Medical Products, which sought protection from creditors in March, ramped up capacity to make 120 million vials a year during the pandemic. By the time the facility was ready, demand for COVID-19 vaccines had tapered. And vaccine distribution ended up favoring syringes over vials.

Rialto Bioenergy Enters Chapter 11

Submitted by jhartgen@abi.org on

Anaergia Inc. has announced that one of its subsidiaries, Rialto Bioenergy Facility LLC (RBF), has initiated voluntary chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court for the Southern District of California, Recycling Today reported. RBF anticipates that, during the restructuring, it will continue operating its multi-feedstock bioenergy facility in Rialto, Calif., which can convert up to 700 tons per day of organic waste, such as food and yard waste and biosolids, into renewable natural gas (RNG) with the capability to generate renewable electricity, soil amendments and fertilizer. RBF, with offices in Carlsbad and a facility in Rialto, California, is 51-percent owned by Anaergia Services LLC, a wholly-owned Anaergia subsidiary. As a result of a lack of feedstock available to the facility, RBF has been unable to produce sufficient revenue to cover its costs and debt service. Anaergia says the feedstock shortfall is due to a delay in the implementation and enforcement of laws requiring organic waste diversion from landfills by the city of Los Angeles as required under its contracts with private waste management companies, as well under California’s SB 1383. The company says feedstock ramp-up is slow industry-wide.

KKR-Backed GenesisCare Preps for Bankruptcy Filing Within Days

Submitted by jhartgen@abi.org on

GenesisCare, a provider of cancer-care services backed by KKR, is preparing to file for bankruptcy within days, WSJ Pro Bankruptcy reported. The Australia-based company, which also operates in the U.S. and Europe, is in talks to receive roughly $200 million in new financing to see it through bankruptcy. GenesisCare is advised by lawyers from Kirkland & Ellis. China Resources Group is also an owner of the company. GenesisCare has been struggling under a debt load in part stemming from its $1.5 billion acquisition of 21st Century Oncology in 2020. Healthcare service provider 21st Century Oncology filed for bankruptcy in 2017, blaming changes in insurance reimbursement practices in addition to government penalties and settlements. It emerged from chapter 11 in 2019. Since October, S&P Global has cut GenesisCare’s credit ratings twice, each time pushing it one notch deeper into distressed territory, raising expectations that the company would default.

Purdue Pharma to Sell Consumer Business for $397 Mln

Submitted by ckanon@abi.org on
Bankrupt Purdue Pharma received a U.S. judge’s permission to sell its consumer health business for $397 million to a subsidiary of Arcadia Consumer Healthcare, Reuters reported. Bankruptcy Judge Sean Lane approved Purdue's sale of Avrio Health at a hearing, allowing Purdue to begin liquidating its assets while it awaits a final ruling on a $10 billion settlement that would devote the company's remaining resources to combating the U.S. opioid epidemic. Purdue's creditors' committee has pushed the company to use the proceeds from the sale to get started on that effort by compensating victims of the opioid crisis and funding addiction treatment programs. Purdue attorney Eli Vonnegut said that the company supports that goal, but will need to build consensus among various stakeholders in its bankruptcy first. Purdue is hesitant to take that step while its future is uncertain and its bankruptcy plan is tied up in appeals, Vonnegut said. Purdue filed for bankruptcy in 2019 to resolve thousands of lawsuits alleging that its opioid painkiller OxyContin kickstarted an epidemic that has caused more than 500,000 U.S. overdose deaths over two decades. Purdue's effort to settle the lawsuits in bankruptcy has been stalled by appeals challenging the company's effort to shield its owners, members of the wealthy Sackler family, from liability in exchange for a $6 billion contribution to Purdue's settlement. (Subscription required.)

Hazel Hawkins Memorial Hospital Approves Chapter 9 Filing

Submitted by ckanon@abi.org on
The San Benito (Calif.) Health Care District, which oversees Hazel Hawkins Memorial Hospital, unanimously voted to file for chapter 9, KSBW reported. The hospital first declared a fiscal emergency in November 2022 that would authorize a bankruptcy filing, but hospital management did not pursue bankruptcy until they first looked at short-term solutions. “This is our final alternative to really fix the systemic issues that are plaguing the district,” said Marcus Young, Hazel Hawkins spokesperson. “We want this community to know that our hospital is open and caring for patients every day — we are not closing. From the very start, our goals have been clear: find a way to continue to offer the best care for our community. This filing is one of the ways we can achieve that goal.” According to the hospital, the bankruptcy process will provide four key components: resolves key contract issues relating to its self-inured status for health care benefits for employees; the filing allows the hospital to remain open and fully operational during the process; accelerates the search for a partner or a buyer; and the court can appoint an ombudsman to ensure a high level of care provided by the hospital. Since November 2022, the hospital has raised more than $11 million through cost savings, loans and prepayments. Hospital leaders say that this isn’t enough and will only last them through summer. One example of the hospital’s “systemic issues” that got them to this point is its self-insured status for employee health care benefits. The San Benito County Board of Supervisors are now considering entering into a nondisclosure agreement with the hospital in an effort to help connect them with a potential partner.

Fight Continues for Affordable Insulin

Submitted by ckanon@abi.org on
On May 10, a dozen or so diabetics gathered in the shade on the steps of the U.S. Senate Hart Building to hear testimony about the price of prescription drugs, with a focus on insulin, at a meeting of the Senate Committee on Health, Education, Labor and Pensions (the HELP Committee), Jacobin.com reported. The CEOs of all three major insulin manufacturers (Eli Lilly, Sanofi and Novo Nordisk), as well as executives from the three largest pharmacy benefit managers (PBMs), were inside, preparing to testify about the cost of insulin and other drugs. Due to a decade-long fight to protest price gouging and raise awareness, insulin has become a centerpiece in the fight for universal health care. Over the past three years, 22 states and Washington, D.C., have passed laws capping the co-pays that insurers can charge patients for insulin prescriptions. With the enactment of the Inflation Reduction Act this year, seniors on Medicare have had their insulin co-pays capped to $35 a month per prescription, drugmakers will be penalized for overcharging for prescriptions filled through Medicaid, and diabetics on certain high-deductible plans now pay less for insulin before their deductibles are met. Most notably, the hearing took place a month after all three major insulin-producers announced expansions to their coupon programs and price reductions on some of their insulins. Yet far too many diabetics still lack access to affordable insulin. As of May 2023, only one brand of insulin — Eli Lilly’s Lispro — has actually seen its price reduced. According to ongoing research by the nonprofit T1International, no respondent to its survey was able to access the low-price insulin before the hearing took place.
Article Tags

Buffalo Billion’s Athenex Files for Bankruptcy

Submitted by ckanon@abi.org on
Once billed as a “game-changer” for Western New York by former governor Andrew Cuomo, Athenex has filed for bankruptcy and signaled to state labor authorities that 123 employees will be laid off in three phases ending in August, WIVB reported. The global biopharmaceutical company had offices in the Conventus Building on Main Street in downtown Buffalo and in Clarence. The doors will close on Aug. 10, ending a 20-year run that began in a University at Buffalo chemistry laboratory with co-founder David Hangauer. “Our office is committed to supporting impacted workers and families and encourages workers to contact the New York State Department of Labor for information on employment resources,” a spokesman for Gov. Kathy Hochul said. Cuomo, through his Buffalo Billion economic development initiative, infused $200 million in subsidies to build Athenex a new manufacturing facility in Dunkirk. Another $25 million went to design space in the Conventus Building for its headquarters. Cuomo said Athenex would create 1,400 jobs in Western New York. “Western New York’s economic transformation has captured the attention of companies and investors around the globe,” Cuomo said on Feb. 11, 2016, when he announced the project. But the company never met that job promise, and Athenex faced numerous setbacks over the years that proved too much to overcome.
Article Tags

California Hospital Weighs Bankruptcy

Submitted by jhartgen@abi.org on

Hollister, Calif.-based Hazel Hawkins Memorial Hospital will decide whether or not it will file a chapter 9 bankruptcy case at the San Benito Health Care District board meeting on May 22, local news outlet KSBW reported May 16, according to Becker's Hospital CFO Report. A November fiscal emergency declaration authorized a chapter 9 filing but the hospital district decided to focus on short-term financial stabilization and creditor negotiations, according to the report. In the last six months, it has recorded more than $11 million in cost savings, loans and prepayments to support the district through summer. In this instance, the hospital district would be able to continue operations without disruption, including caring for patients, operating its facilities, and making payroll, according to the report. The hospital district is continuing cost-saving efforts ahead of a potential strategic partnership with a larger entity.